23 Feb HEALIOS
Sarah Busch, Ph.D., Chief Scientific Officer
Oct. 6 | 2:30pm | FLW Ballroom F
Tokyo, Japan
(TSE: 4593)
Healios is a clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing invimestrocel (HLCM051), a proprietary cell product comprised of multipotent adult progenitor cells (“MAPCs”) derived from the bone marrow of healthy adult donors. Healios is advancing invimestrocel globally for ischemic stroke, ARDS, and trauma. The company has confirmed its path to conditional approval in Japan for the use of invimestrocel for ARDS and is preparing to file for approval and for commercial launch.
